Lp-PLA2-IN-3 is a potent and orally bioavailable lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC 50 of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2). In Vivo Lp-PLA2-IN-3 (3 mg/kg; p.o.) treatment shows the C max , AUC 0-24h , t 1/2 and F were 0.27 μg/mL, 3.4 μg h/mL, 7.7 hours and 35.5%, respectively . Lp-PLA2-IN-3 (1 mg/kg; i.v.) treatment shows the CL, Vss, and t 1/2 were 3.1mL/min/kg, 0.3 L/kg, 4 hours, respectively . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Sprague−Dawley (SD) rats (180-220 g) Dosage: 3 mg/kg Administration: p.o. (Pharmacokinetic Analysis) Result: The C max , AUC 0-24h , t 1/2 and F were 0.27 μg/mL, 6.2 μg h/mL, 7.7 hours and 35.5%, respectively. Form:Solid
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
Lp-PLA2-IN-3
CAS number：2196245-16-4 molecular formula：C20H13ClF3N3O3S
overview
compound introduction
Specs
| Chinese alias | 脂蛋白PLA2-IN-3 | ||
| English alias | - | ||
| CAS number | 2196245-16-4 | molecular formula | C20H13ClF3N3O3S |
| molecular weight | 467.85 g/mol | Exact mass | ≥99% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
